Skip to Accessibility Tools Skip to Content Skip to Footer

Patient Voices Needed for CGRP Insurance Coverage

Patients with migraine disease are being asked to share their stories for considerartion during a review of a new CGRP (calcitonin-gene-related peptide) medication by the Institute of Clinical and Economic Review (ICER).

What is ICER?

The purpose of ICER is to assess the cost-effectiveness of medical therapies and medicines. At the conclusion of this migraine disease review, ICER will publish a report on the cost-effectiveness of CGRP, a new class of drugs that is currently being reviewed by the FDA for approval.

ICER’s report will be used by insurance companies when determining how they will cover CGRP medicines, which could ultimately affect a patient’s access to these medications.

How much will CGRP cost?

ICER will be conducting research for their report from researchers, health economists, biotech companies, doctors and patients. These are the types of questions that will be influenced by this ICER report:

  • Will insurance companies pay for CGRP under the plans they offer?
  • What price will insurance companies be willing to pay for CGRP medicines?
  • How much of the cost will patients be expected to cover for these new medicines?
  • Will insurance companies require patients to try and fail on other medications before being approved for CGRP medicines?

Patient voices needed by November 30

It is important that the patient voice is heard. The stigma surrounding migraine and its debilitating effects are often dismissed. This is a chance for you to discuss how migraine disease affects your life. Share your frustrations over the limited effectiveness and the side-effects of current migraine medications and express the patient need for new and better treatments for migraine disease.

If you would like to give your input to ICER, there is a very short time period in which to participate. The deadline is Thursday, November 30, 2017 at 5:00pm ET.

The online form for patients to answer questions and submit input to ICER can be accessed here.

For further guidance on the key points to convey to ICER, please visit the Headache and Migraine Policy Forum for tips on how to fill out the form: The Headache and Migraine Policy Forum has prepared this information and guidance here.

Comments

  • Shoshana Lipson
    1 year ago

    The new deadline for us to submit is May 8, 2018. Try to get your migraine journey information in, and spread the word!

  • Allistar42
    1 year ago

    I wish I’d seen this in time. I’m finishing a clinical trial and gave never used anything so effective.

  • Shoshana Lipson
    1 year ago
  • ARC
    2 years ago

    Has there been any news on the price tag for CGRP treatment as of late?

  • Allistar42
    1 year ago

    I don’t know about patient costs, but some speculation that it will run about 8k annually.

  • alexmeyers
    2 years ago

    I’ve just submitted my input – when I hit ‘submit’, the page refreshed with the form blank, and no ‘Thank you for your input!’ or “Submission successful” or any such message. Do y’all know if this is normal, or if I have to submit it all again (God, I hope not. It took forever.) Thank you!

  • Katie M. Golden moderator
    2 years ago

    Alex, thanks so much for giving your input!!
    After you submit it, the page goes back to the original form submission page. However, if you scroll down, it will say “Thank you for submitting your input for ICER’s upcoming review.”

    And then you shouldn’t see the form again.
    If you’re not sure if it went through, email publiccomments@icer-review.org

    I hope this helps and thanks so much for taking the time to give your input!
    -Katie

  • Poll